Form 4: Cytokinetics CEO Sells Shares
Insider Transaction (Form 4)
Robert I Blum, President & CEO and a Director of Cytokinetics Inc, sold 7,500 shares of common stock on July 27, 2026 for $80.87 per share.
Summary
- Option exercise/conversion: acquired 7,500 Common Stock at $10.60 ($79,500) on July 27, 2026; holds 385,320 after (Direct).
- Open-market sale: disposed of 7,500 Common Stock at $80.87 ($606,525) on July 27, 2026; holds 377,820 after (Direct).
- Option exercise/conversion: disposed of 7,500 Non-Qualified Stock Option (Right to Buy) on July 27, 2026; holds 179,245 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $606,525 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Robert I Blum — Director, Officer (President & CEO)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-07-27 | Option exercise/conversion | Common Stock | 7,500 | $11 | $79.5K | 385,320 |
| 2026-07-27 | Open-market sale | Common Stock | 7,500 | $81 | $606.5K | 377,820 |
| 2026-07-27 | Option exercise/conversion | Non-Qualified Stock Option (Right to Buy) | 7,500 | — | — | 179,245 |
Key Dates
| Date | Description |
|---|---|
| 2026-07-27 | Option exercise/conversion (7,500 shares) |
| 2026-07-27 | Open-market sale (7,500 shares) |
| 2026-07-27 | Option exercise/conversion (7,500 shares) |
Keywords
insider transaction, Form 4, CYTK, CYTOKINETICS INC, bearish, Robert I Blum
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.